Patent ID: 9657092
Date: 2017-05-23
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. An in vitro method for designing a customized therapy for a subject diagnosed with cancer which comprises: a. determining the levels of the S100A4 protein or of a variant thereof in serum or synovial fluid of said subject and b. comparing the levels of S100A4 protein with a reference value obtained from healthy individuals, wherein a statistically significant increase of the levels of S100A4 protein or of a variant thereof with respect to said reference value is indicative that the patient is to be treated with a specific anti-S100A4 antibody having anti-angiogenic activity or a fragment thereof which substantially preserves the anti-angiogenic activity of said antibody wherein the antibody is selected from the group consisting of: (a) an antibody that recognizes an epitope of S100A4 comprising the sequence ELPSFLGKRT (SEQ ID NO: 3), (b) an antibody that recognizes an epitope of S100A4 comprising the sequence EGFPDKQPRKK (SEQ ID NO: 24) and (c) an antibody produced by the hybridoma ECACC 11051804.